A First-in-Human Study to Assess the Safety and Tolerability of PDNO

Inclusion Criteria: * Willing and able to give written informed consent for participation in the study * Healthy male and female subjects aged 18 to 45 years inclusive at screening * Body Mass Index (BMI) ≥ 18.5 and ≤ 30.0 kg/m\^2 at screening * Clinically normal medical history, physical findings, ECG and laboratory values * Male subjects and women of non-childbearing potential may be included in the study. Male subjects must be willing to use condom or be vasectomised or practice sexual abstinence to prevent pregnancy and drug exposure of a female partner and refrain from donating sperm from the date of dosing until 3 months after dosing with the IMP. Their female partner of child-bearing potential must use contraceptive methods. * Women of non-childbearing potential are defined as pre-menopausal females who are sterilised or postmenopausal Exclusion Criteria: * History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, might interfere with the drug absorption, distribution, metabolism or excretion of the drug or influence the results or the subject's ability to participate in the study * Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of IMP * Malignancy within the past 5 years * Any planned major surgery within the duration of the study * Any positive result on screening for serum hepatit…